Luvesilocin

Luvesilocin
Clinical data
Other names	RE-104; RE104; FT-104; FT104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Routes of; administration	Oral, subcutaneous injection
Drug class	Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Metabolites	• 4-HO-DiPT
Onset of action	≤1 hour (s.c.Tooltip subcutaneous injection)
Elimination half-life	• Luvesilocin: 0.43–0.64 hours (s.c.Tooltip subcutaneous injection); • 4-HO-DiPT: 2.7–4.1 hours (s.c.Tooltip subcutaneous injection)
Duration of action	3.6 hours (range ~3–4 hours) (s.c.Tooltip subcutaneous injection)
Identifiers
	IUPAC name 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate;
CAS Number	2756001-39-3 ;
PubChem CID	162510634;
ChemSpider	129909577;
UNII	64JU3Z4Q2;
ChEMBL	ChEMBL5425653;
Chemical and physical data
Formula	C21H30N2O
Molar mass	326.484 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C;
	InChI InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25); Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N;

Luvesilocin, also known as RE104 and FT-104, as well as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families which is under development for the treatment of psychiatric disorders. It is taken orally or by subcutaneous injection.

Luvesilocin was first described in the literature in 2021. It is under development for the treatment of postpartum depression and treatment-resistant depression. As of September 2025, the drug has reached phase 2 clinical trials. A phase 3 trial is planned for 2026.